Discovery of novel inhibitors of 11β-hydroxysteroid dehydrogenase type 1 by docking and pharmacophore modeling

11β-hydroxysteroid dehydrogenase type 1 (11β-HSD1) is a potential target for treatment of diabetes and metabolic syndrome. Docking and pharmacophore modeling have been used to discover novel inhibitors of 11β-HSD1. Several compounds, with large structural diversity and good potency against 11β-HSD1, have been found and their potency was determined by the enzyme assay. New scaffolds of 11β-HSD1 inhibitors are also reported.

Docking and pharmacophore Modeling were used to discover novel inhibitors of 11β-HSD1. Several compounds with large structural diversity and good potency were found. New scaffolds are reported.Figure optionsDownload as PowerPoint slide